Sign up to save your podcasts
Or
Share Life Science Today 043 – Charles River, IQVIA, Agios, Alloy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Life Science Today 043 – Charles River, IQVIA, Agios, Alloy
Originally Published as The Niche Podcast
Charles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-043-1
https://tinyurl.com/Niche-043-2
https://tinyurl.com/Niche-043-3
https://tinyurl.com/Niche-043-4
https://tinyurl.com/Niche-043-5
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
View all episodes
By Noah Goodson, PhD
5
77 ratings
Originally Published as The Niche Podcast
Charles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-043-1
https://tinyurl.com/Niche-043-2
https://tinyurl.com/Niche-043-3
https://tinyurl.com/Niche-043-4
https://tinyurl.com/Niche-043-5
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.